Widespread distribution of tauopathy in preclinical Alzheimer's disease

被引:39
|
作者
Schultz, Stephanie A. [1 ,2 ]
Gordon, Brian A. [2 ,3 ,4 ]
Mishra, Shruti [2 ]
Su, Yi [2 ]
Perrin, Richard J. [3 ,5 ]
Cairns, Nigel J. [3 ,5 ,6 ]
Morris, John C. [3 ,6 ]
Ances, Beau M. [1 ,3 ,6 ]
Benzinger, Tammie L. S. [1 ,2 ,3 ,7 ]
机构
[1] Washington Univ, Sch Med, Div Biol & Biomed Sci, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Psychol & Brain Sci, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA
[6] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[7] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; Tau; Positron emission tomography; Temporal lobe; Parietal lobe; TAU-PET; CEREBROSPINAL-FLUID; A-BETA; ASSOCIATION; PATHOLOGY; METABOLISM; PREDICTION; BIOMARKERS; DEPOSITION; PROFILES;
D O I
10.1016/j.neurobiolaging.2018.08.022
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The objective of this study was to examine the distribution and severity of tau-PET binding in cognitively normal adults with preclinical Alzheimer's disease as determined by positive beta-amyloid PET. F-18-AV-1451 tau-PET data from 109 cognitively normal older adults were processed with 34 cortical and 9 subcortical FreeSurfer regions and averaged across both hemispheres. Individuals were classified as being beta-amyloid positive (N = 25, A+) or negative (N = 84, A-) based on a F-18-AV-45 beta-amyloid-PET standardized uptake value ratio of 1.22. We compared the tau-PET binding in the 2 groups using covariate-adjusted linear regressions. The A+ cohort had higher tau-PET binding within 8 regions: precuneus, amygdala, banks of the superior temporal sulcus, entorhinal cortex, fusiform gyrus, inferior parietal cortex, inferior temporal cortex, and middle temporal cortex. These findings, consistent with preclinical involvement of the medial temporal lobe and parietal lobe and association regions by tauopathy, emphasize that therapies targeting tauopathy in Alzheimer's disease could be considered before the onset of symptoms to prevent or ameliorate cognitive decline. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:177 / 185
页数:9
相关论文
共 50 条
  • [21] Extracellular Vesicle Biology in Alzheimer’s Disease and Related Tauopathy
    Annina M. DeLeo
    Tsuneya Ikezu
    [J]. Journal of Neuroimmune Pharmacology, 2018, 13 : 292 - 308
  • [22] New Beginnings in Alzheimer's Disease: The Most Prevalent Tauopathy
    Hernandez, Felix
    Llorens-Martin, Maria
    Bolos, Marta
    Perez, Mar
    Cuadros, Raquel
    Pallas-Bazarra, Noemi
    Zabala, Juan C.
    Avila, Jesus
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 : S529 - S534
  • [23] TDP-43 and tau concurrence in the entorhinal subfields in primary age-related tauopathy and preclinical Alzheimer's disease
    Llamas-Rodriguez, Josue
    Oltmer, Jan
    Marshall, Michael
    Champion, Samantha
    Frosch, Matthew P.
    Augustinack, Jean C.
    [J]. BRAIN PATHOLOGY, 2023, 33 (04)
  • [24] Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease
    Bransby, Lisa
    Lim, Yen Ying
    Ames, David
    Fowler, Christopher
    Roberston, Joanne
    Harrington, Karra
    Snyder, Peter J.
    Villemagne, Victor L.
    Salvado, Olivier
    Masters, Colin L.
    Maruff, Paul
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 2019, : 591 - 600
  • [25] Neurodegenerative disease with widespread tauopathy and iron accumulation in childhood
    Bonnin, J. M.
    Murrell, J. R.
    Oblak, A. L.
    Sokol, D. K.
    Walsh, L. E.
    Vidal, R. G.
    Goedert, M.
    Ghetti, B.
    [J]. BRAIN PATHOLOGY, 2014, 24 : 66 - 66
  • [26] New Clues to Preclinical Alzheimer's Disease
    Rosenberg, Paul B.
    Lyketsos, Constantine G.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2018, 175 (06): : 493 - 494
  • [27] Preclinical memory markers of Alzheimer's disease
    Rogers, S. A.
    Miller, K. J.
    Dejong, J.
    Ercoli, L.
    Siddarth, P.
    Small, G.
    [J]. CLINICAL NEUROPSYCHOLOGIST, 2006, 20 (03) : 598 - 599
  • [28] Pathology of clinical and preclinical Alzheimer's disease
    Thal, Dietmar Rudolf
    von Arnim, Christine
    Griffin, W. Sue T.
    Yamaguchi, Haruyasu
    Mrak, Robert E.
    Attems, Johannes
    Upadhaya, Ajeet Rijal
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2013, 263 : S137 - S145
  • [29] Depressive symptoms and preclinical Alzheimer's disease
    Bidzan, Leszek
    Bidzan, Mariola
    [J]. ARCHIVES OF PSYCHIATRY AND PSYCHOTHERAPY, 2005, 7 (03): : 13 - 17
  • [30] PREDICTING FALLS OF PRECLINICAL ALZHEIMER'S DISEASE
    Hu, Y.
    Achuck, K.
    Stark, S.
    [J]. GERONTOLOGIST, 2016, 56 : 337 - 337